2025
KRAS G12C-associated immunotherapy benefit in NSCLC is substantially mediated by tobacco-induced tumor mutation burden, not allele-specific effects
Liu M, Townsend J. KRAS G12C-associated immunotherapy benefit in NSCLC is substantially mediated by tobacco-induced tumor mutation burden, not allele-specific effects. Lung Cancer 2025, 108749. DOI: 10.1016/j.lungcan.2025.108749.Peer-Reviewed Original ResearchNon-small cell lung cancerImmune-checkpoint inhibitionTumor mutational burdenMutational burdenG12C mutationLung adenocarcinomaElevated tumor mutation burdenHigh tumor mutational burdenOncogenic potentialCell lung cancerKRAS G12C mutationImmunotherapy benefitICI outcomesSmoking historyLung cancerG12D mutationHazard ratioAllele-specific effectsKRASClinical trendsKRAS G12CResponse rateTumorG12CMutations
2024
Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer
Kasikova L, Rakova J, Hensler M, Lanickova T, Tomankova J, Pasulka J, Drozenova J, Mojzisova K, Fialova A, Vosahlikova S, Laco J, Ryska A, Dundr P, Kocian R, Brtnicky T, Skapa P, Capkova L, Kovar M, Prochazka J, Praznovec I, Koblizek V, Taskova A, Tanaka H, Lischke R, Mendez F, Vachtenheim J, Heinzelmann-Schwarz V, Jacob F, McNeish I, Halaska M, Rob L, Cibula D, Orsulic S, Galluzzi L, Spisek R, Fucikova J. Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer. Nature Communications 2024, 15: 2528. PMID: 38514660, PMCID: PMC10957872, DOI: 10.1038/s41467-024-46873-w.Peer-Reviewed Original ResearchConceptsHigh-grade serous ovarian carcinomaNon-small cell lung carcinomaTertiary lymphoid structuresCD8+ T cellsT-cell phenotypeTumor mutational burdenT cellsLymphoid structuresB cellsCD8+ T cell compartmentCD8+ T cell phenotypesElevated tumor mutation burdenIntratumoral tertiary lymphoid structuresMature tertiary lymphoid structuresPD1+ T cellsFollicular helper T cellsImmunologically hot tumorB cell profileTumor-infiltrating lymphocytesT cell compartmentAssociated with improved outcomesSerous ovarian carcinomaCell lung carcinomaCohort of patientsHelper T cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply